Gout is a chronic inflammatory disease characterized by swollen joints, pain, heat, redness, and joint stiffness. Gout starts with the inflammation of the big toe; however, it can affect several joints of the body such as ankles, heels, knees, wrists, fingers, and elbows. The disease is caused by the deposition of uric acid crystals in joints resulting in inflammation and pain. Other symptoms include increased level of uric acid in blood, uric acid deposition in joint fluids, and arthritis attacks. Diagnostic tests includes blood tests, synovial fluid testing analysis, and differential diagnosis testing. Treatment of gout includes non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine-like drugs, and xanthine oxidase inhibitor. Xanthine oxidase inhibitor includes several drugs such as allopurinol and oxypurinol, which reduces uric acid production and helps control gout. According to an article published by the National Center for Biotechnology Information, gout is becoming more prevalent in United States, United Kingdom, New Zealand, and China. Another article published in the Springer Nature stated that the prevalence of this disease is more in developed countries as compared to other areas of the world. It also stated that men are more prone to gout than women. In 2013, gout affected around 5.8 million people, contributing to nearly 1% to 2% of western population. Raising awareness regarding the disease in adult patients could be a profitable marketing opportunity for gout therapy drug manufacturers. The global gout therapy market will be majorly driven by new product launches during the forecast period. Few pipeline drug in the gout therapy market include PF-06743649 by Pfizer and Verinurad by AstraZeneca. Zurampic (lesinurad) by AstraZeneca received U.S regulatory approval in December 2015. The drug is used in combination with xanthine oxidase inhibitor. Entry of new drug therapies such as Uloric, Krystexxa, Colcrys, and Adenuric are expected to fuel the gout therapy market during the forecast period. Development of novel systemic treatment with enhanced safety and efficiency by drug manufactures is expected to boost the gout therapy market. Additionally, steadily rising pool of arthritic patients worldwide could impel the growth of the market.
The global gout therapy market has been segmented based on drug class, distribution channel, and region. Depending on type of drug therapy, the market has been classified into non-steroidal anti-inflammatory drugs, corticosteroids, colchicine-like drugs, xanthine oxidase inhibitor, and others. The Non-steroidal anti-inflammatory drugs are first-line treatment and are considered as a part of therapy, used to reduce pain caused by the inflammation. Colchicine-like drugs are considered to be second-line therapy, used in patients unable to tolerate NSAIDs. Corticosteroids are injected into swollen joints and are as effective as non-steroidal anti-inflammatory drugs. Allopurinol, Probenecid, and Febuxostat are few other drugs used to reduce pain attacks caused by gout. New launch of combination therapy are expected to support the growth of the global gout therapy market. In terms of distribution channel the market has been categorized into hospitals, diagnostic centers, and clinics. Hospitals and clinics are expected to hold more share as compare to diagnostic centers.
Based on geography, the global gout therapy market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market due to higher prevalence of gout in the regions. The Asia Pacific market is projected to hold second highest share in the market owing to rising prevalence of the disease in China and India. China is estimated to account for the largest share of the gout therapeutics market owing to factors such as improvement in diagnosis rate, growing geriatric population, and increasing arthritic patient pool.
Major players involved in the global gout therapy market include AstraZeneca plc., Boehringer Ingelheim GmbH, Teijin Pharma Ltd., Regeneron Pharmaceuticals, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, and Savient Pharmaceuticals.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.